ADC Therapeutics SA(ADCT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,759 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ADCT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for ADC Therapeutics SA (ADCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADCT at 21.8/100 on a 32-signal composite quality model, placing it at rank #2,759 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (5.9) and profitability (6.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 18.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ADC Therapeutics SA reports quarterly revenue of $19.2M, net income of $-16.6M, free cash flow of $-11.8M. Top institutional holders of ADCT by reported 13-F value include Nantahala Capital Management, Redmile Group, TCG Crossover Management, based on the most recent SEC filings. ADCT trades on the NYSE exchange and files with the SEC under CIK 1771910. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADC Therapeutics SA directly from SEC EDGAR. ADC Therapeutics SA's 13F Pro composite quality score has ranged between 18 and 23 since 2026, currently 21.8 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$19.2M
Net Income
Q2 2026
$-16.6M
Free Cash Flow
Q2 2026
$-11.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+14.9% YoYNet Income
+9.6% YoYOperating Income
+7.0% YoYEPS (Diluted)
+30.9% YoYTotal Assets
+0.4% YoYTotal Debt
Op. Cash Flow
-14.0% YoYFree Cash Flow
-13.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $81.4M +14.9% | $70.8M +1.8% | $69.6M -66.9% | $209.9M | — | — |
| Net Income | $-142.6M +9.6% | $-157.8M +34.2% | $-240.1M -52.8% | $-157.1M | — | — |
| Operating Income | $-121.5M +7.0% | $-130.7M +21.3% | $-166.0M -34.6% | $-123.3M | — | — |
| EPS (Diluted) | $-1.12 +30.9% | $-1.62 +44.9% | $-2.94 -46.3% | $-2.01 | — | — |
| Total Assets | $323.1M +0.4% | $322.0M -9.2% | $354.8M -27.7% | $490.9M -20.6% | $618.0M +20.3% | $513.7M |
| Total Debt | $3.0M | $0.00 | — | — | — | — |
| Operating Cash Flow | $-141.2M -14.0% | $-123.8M -4.3% | $-118.7M +14.2% | $-138.3M | — | — |
| Free Cash Flow | $-141.4M -13.4% | $-124.7M -2.3% | $-121.9M +12.3% | $-139.0M | — | — |
Get alerted when ADCT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ADC Therapeutics SA including:
Top Institutional Holders of ADCT
Nantahala Capital Management, LLC
$13.2M12,326,184 shRedmile Group, LLC
$12.3M11,526,710 shTCG Crossover Management, LLC
$12.2M11,390,175 shProsight Management, LP
$8.4M7,824,749 shBlackRock, Inc.
$7.5M7,020,093 shPoint72 Asset Management, L.P.
$3.9M3,649,144 shMORGAN STANLEY
$3.3M3,051,173 shMILLENNIUM MANAGEMENT LLC
$3.1M2,899,535 shCITADEL ADVISORS LLC
$2.2M2,053,316 shGOLDMAN SACHS GROUP INC
$2.0M1,914,424 sh
| Fund | Value | Shares |
|---|---|---|
| Nantahala Capital Management, LLC | $13.2M | 12,326,184 |
| Redmile Group, LLC | $12.3M | 11,526,710 |
| TCG Crossover Management, LLC | $12.2M | 11,390,175 |
| Prosight Management, LP | $8.4M | 7,824,749 |
| BlackRock, Inc. | $7.5M | 7,020,093 |
| Point72 Asset Management, L.P. | $3.9M | 3,649,144 |
| MORGAN STANLEY | $3.3M | 3,051,173 |
| MILLENNIUM MANAGEMENT LLC | $3.1M | 2,899,535 |
| CITADEL ADVISORS LLC | $2.2M | 2,053,316 |
| GOLDMAN SACHS GROUP INC | $2.0M | 1,914,424 |
Companies Similar to ADCT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ORTHOPEDIATRICS CORP
TELA Bio, Inc.
IDEAYA Biosciences, Inc.
Keros Therapeutics, Inc.
Stereotaxis, Inc.
Pulmonx Corp
Janux Therapeutics, Inc.
Stoke Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ADCT on your watchlist
Track score changes the day ADC Therapeutics SA files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ADCT a good stock to buy?
13F Pro's AI-powered analysis of ADC Therapeutics SA (ADCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADCT are available on the ADCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ADCT is classified as a small company.
Which hedge funds own ADCT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADC Therapeutics SA's investment landscape.